The trial, led by researchers at UCL and UCLH, found that just nine weeks of treatment with pembrolizumab before surgery led to strong and lasting responses in patients with stage two or three colorectal cancer.

No Cancer Recurrence After Nearly Three Years

Early results showed that 59% of patients had no detectable cancer after completing immunotherapy and undergoing surgery. Now, after 33 months of follow-up, none of the patients have experienced a relapse.

This includes both patients whose tumors completely disappeared and those who still had small traces of cancer after treatment. In all cases, the remaining cancer did not grow or spread over time.

This outcome stands in contrast to standard care, where about 25% of patients treated with surgery followed by chemotherapy are expected to see their cancer return within three years. The findings suggest that starting with immunotherapy may offer longer-lasting protection.

Personalized Blood Tests May Predict Treatment Success

Researchers also explored why the treatment worked so well and how to identify patients most likely to benefit. By analyzing blood samples, they developed personalized tests that can detect whether cancer DNA is still present in the bloodstream.

These tests may allow doctors to determine early on whether the treatment has been successful.

Dr. Kai-Keen Shiu, Chief Investigator of the trial from UCL Cancer Institute and a Consultant Medical Oncologist at UCLH, said: “Seeing that no patients have experienced a cancer recurrence after almost three years of follow-up is extremely encouraging and strengthens our confidence that pembrolizumab is a safe and highly effective treatment to improve outcomes in patients with high-risk bowel cancers.

“What is particularly exciting is that we now may be able to predict who will respond to the treatment using personalized blood tests and immune profiling. These tools could help us tailor our approach, identifying patients who are doing well and may need less therapy before and after surgery versus patients at higher risk of disease progression or relapse who need additional treatment.”

Understanding Colon Cancer Risk and Survival

Bowel cancer is the fourth most common cancer in the UK, with about 44,000 new cases each year. While it primarily affects older adults, diagnoses among people under 50 have been rising.

Outcomes depend heavily on how early the cancer is detected. Around 90% of patients with stage one bowel cancer survive at least five years. Survival drops to 65% at stage three and just 10% at stage four. Some tumor types are also more likely to resist treatment and return.

Trial Details and Patient Group

The NEOPRISM-CRC trial included 32 patients with stage two or three colorectal cancer and a specific genetic subtype (MMR deficient/MSI-high bowel cancer). This subtype accounts for about 10-15% of such cases, or roughly 2,000-3,000 patients each year in the UK.

Participants received up to nine weeks of pembrolizumab before undergoing surgery, instead of the usual approach of surgery followed by several months of chemotherapy. They were then monitored over time.

The latest findings were presented at the American Association for Cancer Research (AACR) Annual Meeting 2026 in San Diego. The study involved multiple UK hospitals, with UCL and UCLH leading the research and biotech company Personalis contributing to the analysis.

Why Immunotherapy Works So Well

Scientists also gained new insights into how immunotherapy produces these lasting effects.

Professor Marnix Jansen from UCL Cancer Institute and UCLH said: “These results not only confirm the durability of responses we saw almost three years ago, but also provide crucial biological insights into why immunotherapy is so effective in this setting.”

Researchers found that when tumor DNA disappeared from the blood, patients were far more likely to remain cancer-free long term.

Yanrong Jiang, first author of the study, said: “As a research team, we were thrilled to be able to follow patients very closely using the personalized blood tests. When tumor DNA disappeared from the blood, patients were much more likely to have no cancer remaining, and this matched the long-term results we’re now seeing.

“In addition, we also saw that immune profiling from tumor tissue, before patients start their first cycle of treatment, can help to predict response. We hope these tests may be used to guide treatment decisions in a more practical and timely way.”

Patient Story Highlights Real-World Impact

Christopher Burston, a 73-year-old patient from Portland, Dorset, was diagnosed with colorectal cancer in February 2023 after routine screening detected blood in his stool.

He said: “One came back with indications of blood in my stool. I went through further tests, and it was at the colonoscopy that they identified a cancer in my bowel.”

Soon after his diagnosis, he was offered the chance to join the NEOPRISM trial and chose to participate, traveling to London for treatment.

He received three doses of immunotherapy over nine weeks before undergoing surgery in May 2023. His recovery was smooth, with minimal side effects.

He said: “The outcome of the surgery was essentially that the cancer had melted away, these were the doctor’s words. The immunotherapy had had an almost immediate effect. I saw the images when I had the first colonoscopy and could see it was really quite a substantial lump. So as I say, it wasn’t a minor thing, I was diagnosed with stage 3 cancer.”

Nearly three years later, he remains cancer-free and has returned to his normal routine.

Christopher said: “The recovery went fine. I didn’t have any problems. And since then, I’ve been feeling pretty much back to normal. I feel very lucky that I’ve reached the stage where my main problem is age rather than cancer or any illness.”

Partial meniscectomy is one of the most common orthopedic surgeries worldwide. While its use has declined in Finland in recent years, it remains a routine treatment in many countries.

10-Year Study Finds Worse Outcomes After Surgery

The long-term results paint a concerning picture. Patients who underwent partial meniscectomy did not experience better outcomes than those who had sham surgery. In fact, they tended to do worse.

After a decade, these patients reported more knee symptoms and poorer function. They also showed greater progression of osteoarthritis and were more likely to need additional knee surgery compared to those who did not receive the actual procedure.

Unique Trial Design Strengthens Findings

The Finnish Degenerative Meniscal Lesion Study (FIDELITY) stands out for its rigorous design. It included a sham surgery control group, allowing researchers to directly compare outcomes against a placebo procedure. Participants with degenerative meniscal tears were randomly assigned to receive either partial meniscectomy or sham surgery, and their progress was tracked for 10 years.

Teppo Järvinen, Professor at the University of Helsinki and the principal investigator of the FIDELITY emphasizes the broader significance of the results:

“Our findings suggest that this may be an example of what is known as a medical reversal, where broadly used therapy proves ineffective or even harmful.”

Rethinking the Cause of Knee Pain

The surgery has long been based on the idea that knee pain, especially on the inner side, is caused by a meniscus tear that can be fixed surgically. However, this assumption may not hold up.

“The surgery is based on the assumption that pain in the inside of the knee is caused by a medial meniscus tear, which can be treated surgically. Such reasoning — assumption based on biological credibility — is still very common in medicine but in this case, the assumption does not withstand critical examination. Based on current understanding, pain in various joints, such as the knee joint in this case, is related to degeneration brought about by aging,” says Raine Sihvonen, Specialist in Orthopaedics and Traumatology and the other principal investigator of the FIDELITY study.

Concerns About Risks and Long-Term Harm

Earlier registry and observational studies have already raised red flags about potential downsides of this surgery. These include a higher likelihood of arthroplasty, or joint replacement surgery, and a possible increase in complications after the procedure. However, observational data alone cannot prove cause and effect.

“Several randomized studies have already demonstrated that partial meniscectomy has not improved patients’ symptoms or function in the short (1-2 years) or medium (5 years) term. Regardless, the procedure has remained widely used in many countries,” says Doctoral Researcher and Specialist in Orthopaedics and Traumatology, Dr. Roope Kalske.

Why the Procedure Is Still Widely Used

Despite mounting evidence, changing clinical practice has been slow.

“For nearly a decade, many independent, non-orthopedic organizations providing clinical guidelines have recommended that the procedure should be discontinued. Still, for example, the American Academy of Orthopedic Surgeons (AAOS) and the British Association for Surgery of the Knee (BASK) have continued to endorse the surgery.

“This effectively illustrates how difficult it is to give up inefficient therapies,” Järvinen sums up.

Strong Collaboration Behind the Study

The research was carried out across five hospitals, highlighting strong collaboration and patient commitment. Of the original 146 participants, more than 90% completed the final follow-up phase.

“The study conducted in five hospitals is an example of smooth multicenter collaboration, as well as the commitment of research patients to an interesting project. Of the original 146 participants, more than 90% took part in the final stage of the study,” says the research manager Pirjo Toivonen.

The Finnish Degenerative Meniscal Lesion Study FIDELITY) is part of the broader work of the FICEBO research group in assessing the impact of surgical therapies. The project is a collaboration between the university hospitals of Helsinki, Kuopio and Turku, Hatanpää Hospital in Tampere, Hospital Nova in Jyväskylä and the Finnish Institute for Health and Welfare.

In a recent study exploring the fundamentals of quantum physics, researchers examined how matter behaves at extremely small scales, including atoms, electrons, and photons. The work, led by Cal Poly Physics Department Lecturer Ian Powell, focused on how varying a magnetic field over time can cause matter to exhibit unusual and previously unseen properties.

Powell and student researcher Louis Buchalter, who earned a Cal Poly bachelor’s degree in physics in 2025, published their findings in Physical Review B in a paper titled “Flux-Switching Floquet Engineering.” Their research shows that when magnetic fields are changed in a controlled, time-dependent way, they can generate quantum states that do not exist in materials that remain unchanged over time (remaining in the same state as time elapses).

“On a big-picture level, I would describe this as an advance in our understanding of how time-dependent control can create and organize new forms of quantum matter,” Powell said. “The central idea is that useful quantum properties can depend not just on what a material is, but on how it is driven in time. In our case, we show that periodically changing a magnetic field can produce driven quantum phases with no static counterpart.”

Toward More Stable Quantum Technologies

By carefully timing how magnetic fields are applied, scientists can design quantum systems with properties that are more stable and less vulnerable to “noise” or imperfections. These disruptions are a major challenge in quantum technology, often leading to errors in calculations or system performance.

Powell noted that while the technical details can be difficult to explain outside the field, the broader concept is clear. The findings suggest new ways to create and study these unusual quantum states in controlled settings such as ultracold-atom experiments.

“The most direct industry relevance of our study is to quantum computing and quantum simulation, rather than to a specific end-use sector at this stage,” Powell said. “Any eventual impact on areas like pharmaceuticals, finance, manufacturing or aerospace would likely be indirect, by contributing to the longer-term development of better quantum technologies. To move toward industry use, the next steps would be experimental validation and further work connecting these ideas to realistic quantum-device platforms.”

New Mathematical Patterns in Quantum Systems

Beyond creating new quantum states, the research also identified a mathematical organizing principle that mirrors patterns typically found in higher-dimensional quantum systems. This suggests that relatively simple systems driven by changing conditions could provide new ways to explore more complex quantum physics.

The team also mapped out how these exotic states form, revealing a precise structure in the system’s topological phase diagram. This diagram serves as a visual guide to different stable quantum phases, each defined by fixed topological properties.

Why Quantum Control Matters for Computing

Quantum mechanics allows computing systems to process information in ways that far exceed the capabilities of classical computers. These systems can perform large-scale simulations, analyze vast data sets, and solve complex problems more efficiently.

Magnetic fields play a central role in this process. They are commonly used to control and measure quantum bits (or qubits), the fundamental units of quantum information. Qubits are comparable to the units of 0s and 1s in classicalcomputing (applied in commonplace computing currently) used to represent physical electrical states.

Student Research Experience and Future Work

For Buchalter, participating in the study provided valuable insight into the research process and scientific communication.

“A lot about the process of conducting research and how new research findings are effectively communicated with the broader scientific community.”

“I learned that research is rarely a straightforward process, often requiring persistence and creative problem solving during the course of a research project,” Buchalter said. “I believe our results help demonstrate the power of Floquet engineering for realizing quantum systems with highly-tunable properties, paving the way for further research into periodically driven quantum matter and the development of its applications.”

Buchalter plans to begin a Master of Science program in materials science and engineering at the University of Washington in the fall, where he will focus on experimental studies of quantum matter. He is also considering a future career at a national laboratory working on quantum device development.

“I initially took on the project due to my interest in condensed matter physics, however, I became fascinated with the field of quantum materials through my experience,” Buchalter said. “I am very interested in continuing to study quantum matter and helping develop its applications in electronic and photonic devices.”

In a 2024 interdisciplinary study published in the Journal of Travel Research, ECU researchers applied the theory of entropy to tourism, proposing that positive travel experiences may support physical and mental health in ways that could help slow some signs of aging. The work does not suggest that travel can stop aging, but it frames tourism as more than a break from routine. It may be a way to help the body maintain balance, resilience, and repair.

How Travel Could Influence Aging

Entropy is often described as the universe’s movement toward disorder. In the context of health, the researchers suggest that experiences can either support or disrupt the body’s ability to stay organized and functioning well. Positive travel experiences may help reduce that drift toward disorder, while stressful or unsafe travel may push the body in the opposite direction.

“Aging, as a process, is irreversible. While it can’t be stopped, it can be slowed down,” ECU PhD candidate Ms. Fangli Hu said.

According to Ms. Hu, travel may improve well being by placing people in new environments, encouraging movement, increasing social interaction, and creating positive emotions. Those same ideas already appear in areas such as wellness tourism, health tourism, and yoga tourism.

“Tourism isn’t just about leisure and recreation. It could also contribute to people’s physical and mental health,” Ms. Hu added.

Travel Therapy and the Body’s Defense Systems

Viewed through an entropy lens, travel therapy could become a meaningful health intervention, Ms. Hu said. The idea is that positive travel experiences, as part of a person’s environment, may help the body maintain a healthier low entropy state by influencing four major body systems.

Travel often combines unfamiliar surroundings with relaxing experiences. New settings can stimulate the body, raise metabolic activity, and help activate self organizing processes that keep biological systems working smoothly. These experiences may also prompt the adaptive immune system, which helps the body recognize and respond to outside threats.

Ms. Hu said that this reaction improves the body’s ability to perceive and defend itself against external threats.

“Put simply, the self-defense system becomes more resilient. Hormones conducive to tissue repair and regeneration may be released and promote the self-healing system’s functioning.”

Stress Relief, Movement, and Healthy Aging

Relaxing travel activities may also help reduce chronic stress and calm an overactive immune response. Recreation can ease tension and fatigue in the muscles and joints, supporting metabolic balance and strengthening the body’s ability to resist wear and tear.

This matters because travel is rarely just sitting still. Trips often include walking through cities, hiking trails, climbing, cycling, or simply spending more time on your feet than usual. That physical activity can increase metabolism, energy use, and nutrient movement throughout the body, all of which may support the systems that keep the body repaired and resilient.

“Participating in these activities could enhance the body’s immune function and self-defense capabilities, bolstering its hardiness to external risks. Physical exercise may also improve blood circulation, expedite nutrient transport, and aid waste elimination to collectively maintain an active self-healing system. Moderate exercise is beneficial to the bones, muscles, and joints in addition to supporting the body’s anti-wear-and-tear system,” Ms. Hu said.

A Field That Is Still Taking Shape

Since the 2024 study, related work has continued to explore travel therapy as a possible health and wellness approach. A 2025 research note by Hu and colleagues described travel therapy as an emerging approach in which positive travel experiences may promote well being, while also emphasizing the need to weigh benefits against risks.

Another 2025 paper called for closer collaboration between travel medicine and tourism, reflecting a growing interest in how vacations, health risks, preventive care, and traveler well being overlap. A 2025 systematic review also found that tourism and healthy aging is becoming an important interdisciplinary research area, but remains underexplored and in need of stronger methods and clearer future research directions.

Together, these newer findings support a careful interpretation: travel may offer real health related benefits, especially when it includes movement, social connection, novelty, and restoration, but researchers are still working to understand how strong those effects are and who benefits most.

The Risks Behind the Benefits

The same research also cautions that travel is not automatically healthy. Tourists can face infectious diseases, accidents, injuries, violence, unsafe food or water, and other risks linked to poor planning or unsuitable travel choices.

“Conversely, tourism can involve negative experiences that potentially lead to health problems, paralleling the process of promoting entropy increase. A prominent example is the public health crisis of COVID-19.”

The central message is not that any trip will slow aging. Rather, positive travel experiences may help the body and mind function better by combining novelty, relaxation, physical activity, and social connection. When travel is safe, restorative, and active, it may do more than create memories. It could help support healthier aging from the inside out.

A recent study published in Neurochemistry International offers a surprising possibility. Researchers from Kindai University and partner institutions found that arginine, a naturally occurring amino acid, can reduce the buildup of harmful Aβ proteins in animal models of Alzheimer’s. Arginine also acts as a safe chemical chaperone, helping proteins maintain their proper structure.

The team noted that while arginine is widely available as an over-the-counter supplement, the doses and methods used in this study were specifically designed for research and are not the same as commercial products.

The research group included Graduate Student Kanako Fujii and Professor Yoshitaka Nagai from the Department of Neurology at Kindai University Faculty of Medicine in Osaka, along with Associate Professor Toshihide Takeuchi from the Life Science Research Institute at Kindai University.

Lab and Animal Studies Show Strong Effects

In laboratory experiments, the scientists first showed that arginine can block the formation of Aβ42 aggregates, which are considered especially toxic. The effect increased with higher concentrations.

They then tested oral arginine in two well-established Alzheimer’s models:

• A Drosophila model, expressing Aβ42 with the Arctic mutation (E22G)
• An App^NL-G-F knock-in mouse model, carrying three familial AD mutations

In both cases, arginine treatment reduced the accumulation of Aβ and lessened its harmful effects.

“Our study demonstrates that arginine can suppress Aβ aggregation both in vitro and in vivo,” explains Prof. Nagai. “What makes this finding exciting is that arginine is already known to be clinically safe and inexpensive, making it a highly promising candidate for repositioning as a therapeutic option for AD.”

Improved Brain Health and Reduced Inflammation

In the mouse model, the benefits went beyond reducing protein buildup. Arginine lowered amyloid plaque levels and reduced the amount of insoluble Aβ42 in the brain. Treated mice also performed better in behavioral tests.

The researchers found that arginine reduced the activity of genes linked to pro-inflammatory cytokines, which are associated with neuroinflammation, a major feature of Alzheimer’s disease. This suggests that arginine may not only prevent harmful protein aggregation but also protect brain cells more broadly.

“Our findings open up new possibilities for developing arginine-based strategies for neurodegenerative diseases caused by protein misfolding and aggregation,” notes Prof. Nagai. “Given its excellent safety profile and low cost, arginine could be rapidly translated to clinical trials for Alzheimer’s and potentially other related disorders.”

A Low-Cost Path Toward New Alzheimer’s Treatments

The study highlights the growing interest in drug repositioning, which involves finding new uses for existing, well-established compounds. Because arginine is already used clinically in Japan and has been shown to safely reach the brain, it could bypass some of the early hurdles that slow down traditional drug development.

Still, the researchers caution that more work is needed. Additional preclinical and clinical studies will be required to determine whether these results can be reproduced in humans and to establish the most effective dosing strategies.

Even so, the findings provide strong early evidence that simple nutritional or pharmacological approaches may help reduce amyloid buildup and improve brain function.

Expanding Understanding of Alzheimer’s Biology

Beyond its potential as a treatment, this work sheds new light on how Aβ proteins form and accumulate in the brain. It also points to a practical and cost-effective strategy that could eventually benefit millions of people living with Alzheimer’s worldwide.

Professor Yoshitaka Nagai, a neurologist and Chair of the Department of Neurology at Kindai University Faculty of Medicine in Osaka, focuses his research on neurodegenerative diseases including Alzheimer’s, Parkinson’s, and amyotrophic lateral sclerosis. His work centers on protein misfolding and RNA-related mechanisms, and he has received multiple honors from organizations such as the Japanese Society of Neurochemistry and the Japanese Dementia Society.

This research was supported by the Ministry of Education, Culture, Sports, Science, and Technology (MEXT) (Grant No. 20H05927), Japan Society for the Promotion of Science (JSPS) (Grant Nos. 24H00630, 21H02840, 22H02792, and 25K02432), Japan Science and Technology Agency (JST) Super-Highway Program (SHW2023-03), and National Center of Neurology and Psychiatry.